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Abstract
Background: Little is known about the time to sputum culture conversion in MDR-TB patients co-infected with HIV,
although such patients have, historically, had poor outcomes. We describe culture conversion rates among MDR-TB patients
with and without HIV-co-infection in a TB-endemic, high-HIV prevalent, resource-limited setting.
Methods: Patients with culture-proven MDR-TB were treated with a standardized second-line regimen. Sputum cultures
were taken monthly and conversion was defined as two negative cultures taken at least one month apart. Time-to-
conversion was measured from the day of initiation of MDR-TB therapy. Subjects with HIV received antiretroviral therapy
(ART) regardless of CD4 count.
Results: Among 45 MDR-TB patients, 36 (80%) were HIV-co-infected. Overall, 40 (89%) of the 45 patients culture-converted
within the first six months and there was no difference in the proportion who converted based on HIV status. Median time-
to-conversion was 62 days (IQR 48-111). Among the five patients who did not culture convert, three died, one was
transferred to another facility, and one refused further treatment before completing 6 months of therapy. Thus, no patients
remained persistently culture-positive at 6 months of therapy.
Conclusions: With concurrent second-line TB and ART medications, MDR-TB/HIV co-infected patients can achieve culture
conversion rates and times similar to those reported from HIV-negative patients worldwide. Future studies are needed to
examine whether similar cure rates are achieved at the end of MDR-TB treatment and to determine the optimal use and
timing of ART in the setting of MDR-TB treatment.
Citation: Brust JCM, Lygizos M, Chaiyachati K, Scott M, van der Merwe TL, et al. (2011) Culture Conversion Among HIV Co-Infected Multidrug-Resistant
Tuberculosis Patients in Tugela Ferry, South Africa. PLoS ONE 6(1): e15841. doi:10.1371/journal.pone.0015841
Editor: Madhukar Pai, McGill University, Canada
Received September 27, 2010; Accepted November 26, 2010; Published January 6, 2011
Copyright:  2011 Brust et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: National Institute of Allergy and Infectious Diseases (K23AI083088 to J.C.M.B.); Doris Duke Charitable Foundation (Clinical Scientist Development
Awards to N.S.S. and N.R.G; ORACTA grant to G.H.F.); and the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR). Statistical support was provided by the
Center for AIDS Research (CFAR) of Albert Einstein College of Medicine/Montefiore Medical Center (P30 AI051519). The funders had no role in study design, data
collection and analysis, decision to publish, or preparation of the manuscript. The project described is solely the responsibility of the authors and does not
necessarily represent the official views of the National Institute Of Allergy and Infectious Diseases or the National Institutes of Health.
Competing Interests: U.G.L. has no competing interests with respect to this study. He has consulted for GlaxoSmithKline, Boehringer Ingelheim, Merck Sharp
and Dohme, and AstraZeneca) and has received financial support from these companies to attend research conferences. The current study, however, was not
funded by these or any other pharmaceutical or device companies. None of the companies listed were involved in any part of the study’s design, execution, or
analysis and Dr. Lalloo’s relationship with the listed companies does not affect the authors’ adherence to any of PLoS One’s policies on sharing data and materials.
None of the other authors has any competing or potentially competing interests.
* E-mail: jcmbrust@gmail.com
Introduction
Multidrug-resistant tuberculosis (MDR-TB, resistance to at least
isoniazid and rifampin) isan increasingly importantglobal threat [1],
with an estimated 440,000 cases worldwide in 2008 [2]. Compared
with drug-susceptible TB, MDR-TB is associated with poorer
treatment outcomes because the medications are less potent, cause
greater adverse events, and must be taken for a minimum of 18–24
months. Although the MDR-TB epidemic was initially focused in
Eastern Europe, growing evidence shows that reported cases of
MDR-TB in sub-Saharan Africa are rising rapidly, raising concerns
for a catastrophic convergence with the HIV epidemic [3,4,5].
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historically been lower than those in HIV-negative patients, in
large part due to higher mortality [6,7]. Most studies, however,
were conducted before the availability of antiretroviral therapy
(ART). The addition of ART to MDR-TB treatment may improve
survival and cure rates for MDR-TB/HIV co-infected patients.
Although cure of MDR-TB requires treatment with second-line
TB drugs for a minimum of 18-24 months, conversion of sputum
culture from positive to negative has become a valuable,
intermediate outcome [8,9]. A Latvian study of MDR-TB
demonstrated that subjects who culture converted within 2 months
of treatment initiation were more likely to achieve cure than those
who did not [10], and other studies have demonstrated that
culture conversion is associated with lower rates of relapse and
failure [8]. Although smear microscopy may be more rapid and
less expensive than culture, its use as an intermediate outcome is
severely limited, especially in patients with HIV co-infection, who
are more likely to have paucibacillary disease [11]. As a result,
culture conversion is now being used as an interim outcome for
predicting treatment success in MDR-TB [12]. Few data,
however, are available regarding culture conversion in MDR-TB
and HIV co-infection in the ART era.
South Africa has experienced a dramatic rise in MDR-TB cases
over the past decade. In KwaZulu-Natal (KZN) province, the
MDR-TB caseload increased 10-fold between 2001 and 2007 to a
MDR-TB prevalence of 30 cases per 100,000 population
[13,14,15]. The HIV co-infection rate among MDR-TB cases is
approximately 70% [15]. To address the high MDR-TB
prevalence and rates of HIV co-infection, we established an
integrated community-based treatment program to provide
concurrent MDR-TB and HIV treatment in Tugela Ferry, South
Africa. In this study, we sought to describe culture conversion rates
among the first cohort of HIV co-infected MDR-TB patients
treated concurrently with MDR-TB and antiretroviral therapy in
our program.
Methods
This is a retrospective, observational study of consecutive
patients initiating MDR-TB treatment between Feburary 1, 2008
and February 28, 2009. Patients were eligible if they lived in
Tugela Ferry district, had culture-confirmed MDR-TB, and
started second-line TB treatment. Patients were excluded if they
had resistance to amikacin, kanamycin, capreomycin or any
fluoroquinolone.
Ethics Statement
This study was approved by the institutional review boards at
Albert Einstein College of Medicine, Yale University, the
University of KwaZulu-Natal, and by the KwaZulu-Natal
Department of Health. The data used in this study were collected
as part of routine medical care into the hospital clinical chart. As
these were simply for clinical care, patients were not asked to give
informed consent at the time of these clinical encounters. For the
purposes of this retrospective study, the requirement for informed
consent was waived by the ethics committees listed above, as all
data had been previously collected during the course of routine
medical care and did not pose any additional risks to the patients.
Setting and treatment program
Tugela Ferry is a resource-poor, rural area in KwaZulu-Natal
province, South Africa, with a TB incidence of 1,100 per 100,000
population and MDR-TB incidence of 100 cases per 100,000 in
2007[15].Morethan80%ofMDR-TBcaseswereHIVco-infected.
Patients presenting with signs and symptoms of TB were
evaluated with sputum microscopy, culture and drug-susceptibility
testing (DST), as previously described [16]. Those suspected of
having TB were empirically started on standard first-line TB
therapy while awaiting culture results. Upon culture-confirmation,
MDR-TB patients were treated with a standardized regimen of
kanamycin, ofloxacin, ethionamide, ethambutol, pyrazinamide,
and cycloserine (intensive phase) for 4 months following culture
conversion (defined as two consecutive negative cultures at least
one month apart) and a minimum of 6 months. Patients were
continued on this regimen, without kanamycin, for an additional
18 months (continuation phase). TB drugs were dosed by weight
and modified in response to severe adverse effects. Third-line TB
drugs and surgical treatment were not routinely used. Extensively
drug-resistant (XDR) TB cases were referred to the TB referral
hospital in Durban [17] and were not eligible for this study.
All patients were offered HIV testing and HIV co-infected
patients initiated ART (stavudine, lamivudine, and either efavirenz
or nevirapine) as soon as they were tolerating MDR-TB therapy,
regardless of CD4 cell count.
Following a brief hospital admission for MDR-TB treatment
initiation, patients received treatment as outpatients by modified
directly-observed therapy. Nurses and community health workers
visited patients’ homes daily to administer both MDR-TB and
ART medications during the intensive and continuation phases,
respectively. Patients were seen monthly by a physician in the
MDR-TB/HIV clinic. Sputum culture and drug susceptibility
testing was performed monthly and CD4 count and HIV viral
load were assessed every 6 months. All treatment was free of
charge and patients were reimbursed for travel expenses.
Outcomes and analysis
The primary outcome was the proportion of MDR-TB patients
who culture converted. Secondary outcomes included 1) time to
culture conversion, 2) stratified analysis by HIV status, and 3)
mortality within the first 6 months of MDR TB therapy.
Culture conversion was defined as two consecutive negative
sputum cultures at least one month apart. Timing of culture
conversion was categorized as occurring: (1) on first-line therapy,
before initiating second-line TB drugs (SLDs), (2) within 2 months
of SLD initiation (early conversion), and (3) within 6 months of
SLD initiation. Time-to-conversion was also analyzed using
product limit estimates and Kaplan-Meier curves, where the
time-to-conversion was calculated as the number of days since
initiating second-line TB drugs. Median values were compared
using the Wilcoxon rank-sum test. Patients who culture-converted
on first-line therapy were excluded from this time-to-conversion
analysis.
To identify clinical and demographic predictors of conversion
on first-line TB therapy and early culture conversion, we used a
Cox proportional hazards regression model for the following
variables: age, gender, prior TB treatment, sputum smear status,
HIV-status, BMI, baseline hemoglobin, CD4 count, HIV viral
load, and ART use prior to starting MDR-TB therapy.
Results
Forty-five culture-confirmed MDR-TB patients initiated treat-
ment and met eligibility criteria for this study (table 1). Of these, 30
(67%) werewomen, witha medianage of 33 years (IQR 27-38), and
30 (67%) were sputum smear-positive. Eleven (24%) patients were
resistant only to isoniazid (INH) and rifampin (RIF); 33 (73%) had
resistance to INH, RIF, and streptomycin (SM); and one (2%) had
resistance to INH, RIF, SM and ethambutol. Only 16 (36%)
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previously been treated for MDR-TB with second-line TB drugs.
Thirty-six patients (80%) were HIV co-infected and of these, 21
(60%) were already receiving ART when MDR-TB treatment was
initiated. Eleven patients initiated ART after starting MDR-TB
treatment (median 57 days, range 22–116). The remaining four
co-infected patients did not initiate ART within the first six
months of treatment (two died, one was transferred to another
facility and one had a CD4 count of 935). At MDR-TB treatment
initiation, the median CD4 cell count was 189 cells/mm
3 (IQR:
85-265) and 58% had viral loads that were undetectable (,400
copies/mL; among those with baseline viral load available
[n=12]). HIV-infected patients had a lower median BMI than
HIV-uninfected patients (17 vs. 20.5 kg/m
2, p=0.03). There were
no other significant differences in baseline characteristics between
HIV co-infected and HIV-negative patients.
Culture Conversion
Prior to starting MDR-TB therapy, 11% (4/36) of HIV co-
infected patients and 33% (3/9) of HIV-negative patients
(p=0.13) converted their sputum culture to negative on empiric
first-line TB treatment. One patient was transferred immediately
after the start of therapy and did not have sufficient culture data to
evaluate conversion. Four additional patients had no culture
within 30 days of MDR-TB treatment initiation. Although all four
of these patients remained culture-negative for the duration of
follow-up, the time of conversion could not be identified and these
patients were excluded from further analysis.
Of the remaining 33 patients with a positive culture at the start
of MDR-TB therapy, 29 (88%) achieved culture conversion within
the first 6 months of treatment. These included 23 of 27 (85%)
MDR-TB/HIV co-infected and 6 of 6 (100%) HIV-negative
patients (p=1.0). Of the four HIV co-infected patients who did
not culture convert, three died, and one refused further treatment
within the first six months of treatment. Thus, no patients
remained persistently culture-positive on treatment.
The median time to culture conversion on second-line therapy
was 62 days (IQR 48-111). The median time-to-conversion for
HIV co-infected patients was 54 days (IQR 41-90), whereas for
HIV-negative patients it was 103.5 days (IQR 86-116; Figure 1).
No other patient demographics or clinical characteristics were
associated with early sputum conversion (less than 60 days; data
not shown).
Overall, of the 45 subjects included in this study, five (11%)
were transferred to another facility, one (2%) refused further
treatment, and four (9%) died while receiving therapy. The four
patients who died were all HIV-positive, and death occurred after
a median of 116 days in treatment for MDR-TB (range 1–199
days). As of July 1, 2009, 35 patients (78%) were alive and in
follow-up having been on treatment for a mean of 333 days (SD
112).
Discussion
We examined culture conversion rates among HIV co-infected
and HIV-negative MDR-TB patients receiving treatment in a
rural area of South Africa. Our findings were very favorable,
demonstrating that nearly all patients achieved culture conversion
within the first six months, irrespective of HIV status. Moreover,
the culture conversion time for HIV co-infected patients was
similar to reports of HIV-negative patients in the published
literature. These early data provide optimism that a strategy of
concurrently treating MDR TB and HIV may lead to favorable
outcomes for co-infected patients.
Culture conversion is generally the first goal of MDR-TB therapy
and is used as an early endpoint in MDR-TB studies [12]. Although
most of the data supporting use of this endpoint are from studies in
drug-susceptible TB, Holtz et al. [10] demonstrated a patient-level
relationship between shorter time-to-culture conversion and final
treatment outcome. Others have found a similar association
between culture conversion rates and treatment success [8,9]. Most
published cohorts ofMDR-TBtreatment,however, have had few, if
any, HIV co-infected subjects, and the majority of those that did are
from the 1990s, predating the availability of combination ART
[18,19]. As a result, there are few data available from the ART-era
comparing culture conversion rates and time-to-culture conversion
between HIV co-infected and HIV-negative patients [20].
Table 1. Baseline characteristics by HIV status.
Characteristic All subjects HIV-neg HIV-pos p-value
(n=45) (n=9) (n=36)
Female – n (%) 30 (65) 6 (67) 24 (67) 1.0
Median Age (IQR) 33 (27–38) 28 (20–38) 34 (29–37) 0.26
Median BMI (kg/m
2), median (IQR) 18.8 (15.8–20.3) 20.5 (18.9–22.6) 17 (15.7–19.5) 0.025
Hemoglobin (g/dL), median (IQR) 10.6 (9.2–12.4) 11.6 (10.3–14.6) 10.4 (8.6–12.3) 0.083
HIV-positive – n (%) 36 (80) -- -- --
Median CD4 count at baseline, cells/mm
3 (IQR) -- -- 189 (85-265) --
On ART at start of MDR-TB treatment – n (%) -- -- 21 (60) --
Smear-positive – n (%) 30 (67) 7 (78) 23 (64) 0.70
Any previous TB – n (%) 16 (35.6) 1 (11) 15 (42) 0.13
Previous treatment for MDR-TB – n (%) 3 (6.7) 0 (0) 3 (8.3) 1.0
Mean number of sputum samples sent in first 6 months (SD) 5 (4–6) 7 (5–7) 5 (4–6) 0.18
Median number of days from initial sputum collection
to initation of MDR-TB therapy (IQR)
74 (44–106) 90 (54–113) 69 (44–103) 0.67
IQR: interquartile range; MDR-TB: multidrug-resistant tuberculosis; ART: antiretroviral therapy;
BMI: body mass index.
doi:10.1371/journal.pone.0015841.t001
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between the two groups. No patients in either group remained
persistently culture-positive (i.e., in jeopardy of becoming a
treatment failure). Although a few patients in the HIV group did
not meet official criteria for culture conversion, this was due to the
fact that each suffered a competing outcome (patient either died,
or defaulted) before completing six months of MDR therapy. The
median time to culture conversion in HIV co-infected subjects was
also similar to those of HIV-negative patients published in the
literature worldwide [8,10,21], and comparable to the HIV-
negative subjects in our cohort. Our high rates of culture
conversion add to those recently reported among MDR-TB/
HIV co-infected patients in Lesotho [22], although that group had
higher mortality rates. It will be important to follow these patients’
cultures throughout the continuation phase to be sure that they do
not revert to positive after discontinuation of the injectable agent.
An important limitation of this study is that of survival bias.
Because of the long time required for TB culture and DST,
patients in this study survived a median 74 days from initial
sputum collection to start of appropriate MDR-TB treatment. As
we have previously shown, this delay is associated with extremely
high mortality rates and many patients never receive appropriate
therapy [23]. Nonetheless, the objective of this study was to show
MDR-TB/HIV co-infected patients’ response to concurrent
therapy. Thus, although a sizeable proportion of co-infected
patients may have died prior to receiving therapy, our study is
valuable because it demonstrates that those who do receive
therapy are likely to achieve culture conversion.
Although studies from the 1990s, before the availability of ART,
suggested substantially worse treatment outcomes for HIV co-
infected MDR-TB patients compared to HIV-negative patients
[24], our early findings provide hope that a strategy of integrating
second-line TB therapy and ART will improve MDR-TB cure
rates in HIV co-infected patients. Even though our sample size
was limited and final 24-month treatment outcomes are needed to
definitively demonstrate the effectiveness of this strategy, our high
rates of culture conversion and lower mortality rate pave the way
for improved cure rates in MDR-TB and HIV co-infection, even
in rural, resource-limited settings. Mired by the dual epidemics of
TB and HIV, South Africa now faces a rising tide of MDR-TB/
HIV co-infection and these data should provide welcome news for
the concurrent treatment of both diseases.
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